JP5862560B2 - レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害 - Google Patents

レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害 Download PDF

Info

Publication number
JP5862560B2
JP5862560B2 JP2012511816A JP2012511816A JP5862560B2 JP 5862560 B2 JP5862560 B2 JP 5862560B2 JP 2012511816 A JP2012511816 A JP 2012511816A JP 2012511816 A JP2012511816 A JP 2012511816A JP 5862560 B2 JP5862560 B2 JP 5862560B2
Authority
JP
Japan
Prior art keywords
rap
seq
polypeptide
prp
lrpap1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012511816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012527459A5 (enExample
JP2012527459A (ja
Inventor
ラリサ セルヴェナコワ
ラリサ セルヴェナコワ
オクサナ ヤコブレワ
オクサナ ヤコブレワ
Original Assignee
アメリカン ナショナル レッド クロス
アメリカン ナショナル レッド クロス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アメリカン ナショナル レッド クロス, アメリカン ナショナル レッド クロス filed Critical アメリカン ナショナル レッド クロス
Publication of JP2012527459A publication Critical patent/JP2012527459A/ja
Publication of JP2012527459A5 publication Critical patent/JP2012527459A5/ja
Application granted granted Critical
Publication of JP5862560B2 publication Critical patent/JP5862560B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012511816A 2009-05-21 2010-05-17 レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害 Expired - Fee Related JP5862560B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18040609P 2009-05-21 2009-05-21
US61/180,406 2009-05-21
US21875209P 2009-06-19 2009-06-19
US61/218,752 2009-06-19
PCT/US2010/001455 WO2010134970A1 (en) 2009-05-21 2010-05-17 Inhibition of prion protein propagation by receptor associated protein (rap). its derivatives, mimetics and syntentic peptides

Publications (3)

Publication Number Publication Date
JP2012527459A JP2012527459A (ja) 2012-11-08
JP2012527459A5 JP2012527459A5 (enExample) 2013-07-04
JP5862560B2 true JP5862560B2 (ja) 2016-02-16

Family

ID=43126428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012511816A Expired - Fee Related JP5862560B2 (ja) 2009-05-21 2010-05-17 レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害

Country Status (6)

Country Link
US (1) US9051390B2 (enExample)
EP (1) EP2432487B1 (enExample)
JP (1) JP5862560B2 (enExample)
AU (1) AU2010250104B2 (enExample)
CA (1) CA2755948A1 (enExample)
WO (1) WO2010134970A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017218897A1 (en) * 2016-06-17 2017-12-21 The Trustees Of The University Of Pennsylvania Novel 1gg binding peptides and multifunctional antigen-binding proteins comprising the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
PT1953551E (pt) * 2002-12-03 2014-05-06 Pathogen Removal & Diagnostic Technologies Inc Ligandos a proteína de prião e métodos de uso
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues

Also Published As

Publication number Publication date
US20120135936A1 (en) 2012-05-31
AU2010250104B2 (en) 2014-04-24
AU2010250104A1 (en) 2011-10-27
JP2012527459A (ja) 2012-11-08
US9051390B2 (en) 2015-06-09
EP2432487A4 (en) 2013-01-02
EP2432487B1 (en) 2016-03-02
EP2432487A1 (en) 2012-03-28
WO2010134970A8 (en) 2011-11-10
WO2010134970A1 (en) 2010-11-25
CA2755948A1 (en) 2010-11-25
AU2010250104A8 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
Mookherjee et al. Antimicrobial host defence peptides: functions and clinical potential
Chaplot et al. Secreted chaperones in neurodegeneration
Xu et al. Methamphetamine exposure triggers apoptosis and autophagy in neuronal cells by activating the C/EBPβ‐related signaling pathway
CN108431021B (zh) 具有神经元损失预防和再生效果的肽以及包含该肽的组合物
Yong et al. Neuroprotective effects of lactoferrin in Alzheimer’s and Parkinson’s diseases: A narrative review
Maezawa et al. Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment‐associated cytotoxicity
Lu et al. Transferrin is responsible for mediating the effects of iron ions on the regulation of anterior pharynx-defective-1α/β and Presenilin 1 expression via PGE2 and PGD2 at the early stage of Alzheimer’s Disease
Ayyubova APOE4 is a risk factor and potential therapeutic target for Alzheimer's disease
WO2011147889A1 (en) Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
Kesharwani et al. Interplay between mitophagy and inflammasomes in neurological disorders
Guan et al. As a potential therapeutic target, C1q induces synapse loss via inflammasome-activating apoptotic and mitochondria impairment mechanisms in Alzheimer’s disease
JP5862560B2 (ja) レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害
WO2006036410A2 (en) Protection from and treatment of prion protein infection
Su et al. Antimicrobial peptides in the brain
Li The role of antimicrobial peptides in cardiovascular physiology and disease
Wang et al. Expression and distribution of laminin receptor precursor/laminin receptor in rabbit tissues
US20090304675A1 (en) Method of modulation of mullerian inhibitory substance (mis) receptor for the treatment of neurodegenerative diseases
KR101306157B1 (ko) 사이클로펜타펩타이드를 유효성분으로 포함하는 종양의 예방 또는 치료용 조성물
Usama et al. Molecular genetics of prions
Borbély Development of Non-Transgenic Animal Models of Alzheimer’s Disease and Investigation of Drug Candidates for its Treatment
US20200255492A1 (en) Leptin peptides and their use for treating neurological disorders
US20230390359A1 (en) Use of reelin for treating cardiac diseases
Swati The Role of TGF Beta Proteins In The Regulation of Skeletal Muscle Mass
Ramanathan Cathelicidins: Antimicrobial Peptides
WO2022164823A2 (en) Inhibition of degranulation of neutrophil cells in covid-19 patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151214

R150 Certificate of patent or registration of utility model

Ref document number: 5862560

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees